Guidewire Beats Revenue & EPS Forecasts, But Stock Falls on Full-Year ARR Outlook
Guidewire beat Q3 earnings, but a weak ARR outlook worried investors, sending shares down despite strong revenue growth.
NOTRELOAD AI
Biogen’s Salanersen Wins FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
Biogen’s new SMA drug Salanersen shows strong early results, helping kids move better. FDA fast-tracks it with Breakthrough status.
Liquidia Gets Bullish Signal from Hikma vs Amarin Ruling
Raymond James reiterates Strong Buy rating and $68 target on Liquidia after the Supreme Court’s positive Hikma v. Amarin decision.
Lululemon Beats Q1 Expectations But Warns of Tough Road Ahead
Lululemon beat Q1 2026 expectations with $2.5B revenue but slashed full-year and Q2 guidance due to weak US demand.
Enobosarm Grabs Novo Nordisk’s Attention: Veru’s Big Obesity Breakthrough
Veru partnered with Novo Nordisk to test enobosarm + Wegovy for fat loss while keeping muscle; stock surged.
Amneal Wins FDA Approval for Ready-to-Use Romidepsin Injection – No Mixing Needed!
FDA approves Amneal ready-to-use romidepsin injection for rare skin cancer, simplifying use and giving 180-day exclusivity.